Dynavax hepatitis C drug brings antiviral response in early-stage trial

01/26/2010 | Reuters

An early-stage study showed that high doses of Dynavax Technologies' hepatitis C drug reduced the severity of viral infection in patients who also received other antivirals. The treatment, SD-101, outperformed older drugs in stimulating the production of two forms of interferons, which help the immune system fight viruses and other pathogens.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC